Zobrazeno 1 - 10
of 28
pro vyhledávání: '"ALBERTO CARRAL"'
Autor:
Jordi Rubió-Casadevall, Beatriz Cirauqui Cirauqui, Javier Martinez Trufero, Maria Plana Serrahima, Almudena García Castaño, Alberto Carral Maseda, Lara Iglesias Docampo, Pedro Pérez Segura, Isaac Ceballos Lenza, Vanesa Gutiérrez Calderón, José Fuster Salvà, Carolina Pena Álvarez, Irene Hernandez, Edel del Barco Morillo, Manuel Chaves Conde, Joaquina Martínez Galán, Marisa Durán Sánchez, Vanesa Quiroga, Eugenia Ortega, Ricard Mesia
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectivesThe aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m2 weekly and cetuximab 400 mg/m2 loading dose, and then 250 mg/m2 weekly) as first-line treatment for patients with recurrent/metastatic squamous cel
Externí odkaz:
https://doaj.org/article/2c2ce3b877f44930902325a31aadefe0
Autor:
Nieves Martínez-Lago, Ana Fernández-Montes, Marta Covela, Elena M. Brozos, Juan De la Cámara, José C. Méndez Méndez, Mónica Jorge-Fernández, Antía Cousillas Castiñeiras, Cristina Reboredo, David Arias Ron, María L. Pellón Augusto, Paula González Villarroel, Begoña Graña, Mercedes Salgado Fernández, Alberto Carral Maseda, Francisca Vázquez Rivera, Sonia Candamio Folgar, Margarita Reboredo López, On behalf of the Galician Research Group on Digestive Tumors (GITuD)
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of
Externí odkaz:
https://doaj.org/article/0205a0ed5fdf486f96be2430c7159205
Autor:
Baliga, Sujith, Abou-Foul, Ahmad K., Parente, Pablo, Szturz, Petr, Thariat, Juliette, Shreenivas, Aditya, Nankivell, Paul, Bertolini, Federica, Biau, Julian, Blakaj, Dukagjin, Brennan, Sinead, Brunet, Aina, De Oliveira, Thiago Bueno, Burtness, Barbara, Maseda, Alberto Carral, Chow, Velda Ling-Yu, Chua, Melvin LK, de Ridder, Mischa, Garikipati, Satya, Hanai, Nobuhiro, Ho, Francis Cho Hao, Huang, Shao Hui, Kiyota, Naomi, Klinghammer, Konrad, Kowalski, Luiz P., Kwong, Dora L, McDowell, Lachlan J, Merlano, Marco Carlo, Nair, Sudhir, Economopoulou, Panagiota, Overgaard, Jens, Psyrri, Amanda, Tribius, Silke, Waldron, John, Yom, Sue S., Mehanna, Hisham
Publikováno v:
In European Journal of Cancer May 2024 203
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Metcalf, Anagha Gogate, Bryan Bennett, Zia Poonja, Grant Stewart, Ana Medina Colmenero, Petr Szturz, Courtney Carrington, Clara Castro, Eric Gemmen, Ashley Lau, Alberto Carral Maseda, Eric Winquist, Virginia Arrazubi, Desiree Hao, Audrey Cook, Joaquina Martinez Galan, Lisardo Ugidos, David Fernández Garay, David Gutierrez Abad, Robert
Publikováno v:
Cancers; Volume 15; Issue 14; Pages: 3552
This study examined the real-world use of nivolumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). This was a multinational retrospective study (VOLUME) assessing treatment effectiveness and safety out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::38dfbd3764c31b0eeaca41ab0581e2f4
Autor:
SANTIAGO AGUIN, ALBERTO CARRAL, LETICIA IGLESIAS, CAROLINA PENA, AUREA MOLINA, MARINHA COSTA, MARTA COVELA, JESUS GARCIA GOMEZ, RAMÓN GARCIA ARROYO, GERARDO HUIDOBRO, ROCÍO VILCHES SIMO, ANA MEDINA
Publikováno v:
Cancer Diagn Progn
Background/Aim: Prior immune-checkpoint inhibitors, weekly paclitaxel-cetuximab was one of the few options for platinum-ineligible patients with recurrent/ metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). This real-world study ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8ca9e65dce1e059f18c814a6b5719ef
https://europepmc.org/articles/PMC9949534/
https://europepmc.org/articles/PMC9949534/
Autor:
Antonio Rueda Domínguez, Beatriz Cirauqui, Almudena García Castaño, Ruth Alvarez Cabellos, Alberto Carral Maseda, Beatriz Castelo Fernández, Leticia Iglesias Rey, Jordi Rubió-Casadevall, Virginia Arrazubi, Ricard Mesía
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 24(4)
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7482045cba4328ba732312bc2617c2d5
https://pubmed.ncbi.nlm.nih.gov/35303267
https://pubmed.ncbi.nlm.nih.gov/35303267
Autor:
Lara Iglesias, Ana Belen Enguita, Ramon Yarza, Marisa Durán, Justino Jiménez Almonacid, Neus Baste, Alberto Carral Maseda, Marc Oliva, Pedro Perez Segura, Ana Medina-Colmenero, Beatriz Cirauqui, Virginia Arrazubi, Vanesa Gutierrez Calderon, Javier Martinez-Trufero, Edel del Barco Morillo, Almudena García Castaño, Jordi Rubió-Casadevall, Laura Basterretxea, Irene Brana, Ricard Mesia
Publikováno v:
Journal of Clinical Oncology. 40:e18015-e18015
e18015 Background: PD-L1 is a biomarker of response to anti-PD1 in HNSCC. CA209-7HE trial (NCT04282109) is a randomized, open-label, multicenter, phase II trial including first line R/M HNSCC pts non-eligible for cisplatin-based chemotherapy. Pts wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e41f92494aa6ca696bb3d309c8d46e3
https://doi.org/10.1200/jco.2022.40.16_suppl.e18015
https://doi.org/10.1200/jco.2022.40.16_suppl.e18015